Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ABBV-3067 alone and with ABBV-2222 in adults with cystic fibrosis homozygous for F508del
NL-OMON48171Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of navocaftor and galicaftor in cystic fibrosis (CF) (5 arms), sponsored by AbbVie Inc. Primary endpoint: Change from baseline through Day 29 in overall lung function. Planned start Aug 2019; status: withdrawn.
02
Drugs
navocaftorgalicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON48171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48171.